BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 15283234)

  • 1. A vaccine against coccidioidomycosis is justified and attainable.
    Cole GT; Xue JM; Okeke CN; Tarcha EJ; Basrur V; Schaller RA; Herr RA; Yu JJ; Hung CY
    Med Mycol; 2004 Jun; 42(3):189-216. PubMed ID: 15283234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A genetically engineered live attenuated vaccine of Coccidioides posadasii protects BALB/c mice against coccidioidomycosis.
    Xue J; Chen X; Selby D; Hung CY; Yu JJ; Cole GT
    Infect Immun; 2009 Aug; 77(8):3196-208. PubMed ID: 19487479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A recombinant aspartyl protease of Coccidioides posadasii induces protection against pulmonary coccidioidomycosis in mice.
    Tarcha EJ; Basrur V; Hung CY; Gardner MJ; Cole GT
    Infect Immun; 2006 Jan; 74(1):516-27. PubMed ID: 16369008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coccidioidomycosis: host response and vaccine development.
    Cox RA; Magee DM
    Clin Microbiol Rev; 2004 Oct; 17(4):804-39, table of contents. PubMed ID: 15489350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational Design of T Lymphocyte Epitope-Based Vaccines Against Coccidioides Infection.
    Hurtgen BJ; Hung CY
    Methods Mol Biol; 2017; 1625():45-64. PubMed ID: 28584982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Rise of
    Van Dyke MCC; Thompson GR; Galgiani JN; Barker BM
    Front Immunol; 2019; 10():2188. PubMed ID: 31572393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viable spores of Coccidioides posadasii Δcps1 are required for vaccination and provide long lasting immunity.
    Shubitz LF; Powell DA; Trinh HT; Lewis ML; Orbach MJ; Frelinger JA; Galgiani JN
    Vaccine; 2018 May; 36(23):3375-3380. PubMed ID: 29724507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical identification of vaccine induced protective correlates in human leukocyte antigen expressing transgenic mice infected with Coccidioides posadasii.
    Hurtgen BJ; Castro-Lopez N; Jiménez-Alzate MDP; Cole GT; Hung CY
    Vaccine; 2016 Oct; 34(44):5336-5343. PubMed ID: 27622300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow Cytometric Analysis of Protective T-Cell Response Against Pulmonary Coccidioides Infection.
    Hung CY; Wozniak KL; Cole GT
    Methods Mol Biol; 2016; 1403():551-66. PubMed ID: 27076153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccines against Coccidioides.
    Yoon HJ; Clemons KV
    Korean J Intern Med; 2013 Jul; 28(4):403-7. PubMed ID: 23864796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of two homologous proline-rich proteins of Coccidioides posadasii as candidate vaccines against coccidioidomycosis.
    Herr RA; Hung CY; Cole GT
    Infect Immun; 2007 Dec; 75(12):5777-87. PubMed ID: 17875631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coccidioides immitis and posadasii; A review of their biology, genomics, pathogenesis, and host immunity.
    Kirkland TN; Fierer J
    Virulence; 2018; 9(1):1426-1435. PubMed ID: 30179067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel strategies to enhance vaccine immunity against coccidioidomycosis.
    Cole GT; Hung CY; Sanderson SD; Hurtgen BJ; Wüthrich M; Klein BS; Deepe GS; Ostroff GR; Levitz SM
    PLoS Pathog; 2013; 9(12):e1003768. PubMed ID: 24367252
    [No Abstract]   [Full Text] [Related]  

  • 14. A review of innate and adaptive immunity to coccidioidomycosis.
    Hung CY; Hsu AP; Holland SM; Fierer J
    Med Mycol; 2019 Feb; 57(Supplement_1):S85-S92. PubMed ID: 30690602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans. The Valley Fever Vaccine Study Group.
    Pappagianis D
    Am Rev Respir Dis; 1993 Sep; 148(3):656-60. PubMed ID: 8368636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Both CD4+ and CD8+ T cells can mediate vaccine-induced protection against Coccidioides immitis infection in mice.
    Fierer J; Waters C; Walls L
    J Infect Dis; 2006 May; 193(9):1323-31. PubMed ID: 16586371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and cellular mechanisms of protective immunity to coccidioidomycosis.
    Kirkland TN; Raz E; Datta SK
    Vaccine; 2006 Jan; 24(4):495-500. PubMed ID: 16181709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An agonist of human complement fragment C5a enhances vaccine immunity against Coccidioides infection.
    Hung CY; Hurtgen BJ; Bellecourt M; Sanderson SD; Morgan EL; Cole GT
    Vaccine; 2012 Jun; 30(31):4681-90. PubMed ID: 22575167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CARD9-Associated Dectin-1 and Dectin-2 Are Required for Protective Immunity of a Multivalent Vaccine against
    Campuzano A; Zhang H; Ostroff GR; Dos Santos Dias L; Wüthrich M; Klein BS; Yu JJ; Lara HH; Lopez-Ribot JL; Hung CY
    J Immunol; 2020 Jun; 204(12):3296-3306. PubMed ID: 32358020
    [No Abstract]   [Full Text] [Related]  

  • 20. Seeking a vaccine against Coccidioides immitis and serologic studies: expectations and realities.
    Pappagianis D
    Fungal Genet Biol; 2001 Feb; 32(1):1-9. PubMed ID: 11277621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.